The BMS Commitment to Patients
BMS is committed to transforming patients' lives through science and to addressing unmet needs in dermatology.
Our research on the TYK2 pathway is a preeminent example of BMS leading the way with pathbreaking science to help patients prevail over serious immune-related diseases such as psoriasis.
References
- Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11-27. doi: 10.1007/s00281-015-0539-8
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555
- Diogo D, Bastarache L, Liao KP, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10(4):e012271. doi: 10.1371/journal.pone/0122271
- Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149. doi: 10.1126/scitranslmed.aag1974
- Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13(4):561-571. doi: 10.1016/s1074-7613(00)00055-8
- Richard AJ, Stephens JM. Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol Metab. 2011;22(8):325-332. doi:10.1016/j.tem.2011.03.007